Amphomycin

Cyclic Lipopeptide AntibioticRx: ResearchCompound: Investigational

Also known as: Amphomycin A, Aspartocin, Calcium amphomycin, Glumamycin, L-658,234

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Source Amphomycin at Peptiology

Save 10% with code PEPTI-BOSSRABBIT-10

Shop Now & Save 10% →

Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.

Summary

Amphomycin is a naturally occurring cyclic lipopeptide produced by Streptomyces griseus that exhibits potent activity against Gram‑positive organisms by disrupting cell‑wall assembly. It has never received regulatory approval and is used only in pre‑clinical research.

Mechanism of Action

Binds to undecaprenyl phosphate (bactoprenol), blocking peptidoglycan precursor translocation and inhibiting cell‑wall synthesis in Gram‑positive bacteria

Routes of Administration

IntravenousSubcutaneousTopical

Goals & Uses

  • Gram-positive bacterial infection treatmentAntimicrobialLow
  • treat resistant Gram‑positive infectionsAntibacterialModerate
  • Topical antibacterial applicationAntimicrobialLow
  • Inhibition of peptidoglycan biosynthesis (research tool)Research/mechanistic ProbeModerate

Contraindications

  • Renal impairmentOrgan DysfunctionModerate
  • Known hypersensitivity to amphomycin or related lipopeptidesAllergyHigh

Adverse Effects

  • Hypersensitivity reactionsImmunologicUnknown
  • Injection site reactionsLocalCommon
  • NephrotoxicityRenalRare

Drug Interactions

  • Nephrotoxic agents (e.g., aminoglycosides, NSAIDs)High

Population Constraints

  • Pediatric patientsAgeRelative
  • Pregnant womenReproductiveRelative
  • Patients with pre-existing renal diseaseOrgan DysfunctionRelative

Regulatory Status

  • European UnionUnapprovedNo marketing authorization.
  • United StatesUnapprovedInvestigational use only under IND.
  • United KingdomUnapprovedNot licensed for clinical use.

No FDA, EMA, or MHRA approval; classified as an investigational new drug (IND) only for experimental use.

Evidence & Sources

No sources recorded yet.

Frequently Asked Questions

What is Amphomycin?

Amphomycin is a naturally occurring cyclic lipopeptide produced by Streptomyces griseus that exhibits potent activity against Gram‑positive organisms by disrupting cell‑wall assembly. It has never received regulatory approval and is used only in pre‑clinical research.

What is Amphomycin used for?

Amphomycin is educationally associated with: Gram-positive bacterial infection treatment, treat resistant Gram‑positive infections, Topical antibacterial application, Inhibition of peptidoglycan biosynthesis (research tool). Educational only — not medical advice.

How is Amphomycin administered?

Recorded routes of administration: Intravenous, Subcutaneous, Topical.

What are the potential side effects of Amphomycin?

Reported adverse effects include: Hypersensitivity reactions, Injection site reactions, Nephrotoxicity. This list is not exhaustive — consult a qualified clinician.

Who should avoid Amphomycin?

Recorded contraindications: Renal impairment, Known hypersensitivity to amphomycin or related lipopeptides. Consult a qualified clinician before use.

More in this class